CYP21A2 rs121908743: Understanding the V281L Variant
The rs121908743 variant in the CYP21A2 gene, often referred to as V281L, is a genetic change associated with non-classic congenital adrenal hyperplasia (NCAH). This condition involves a partial deficiency in the enzyme required for cortisol production, which can lead to symptoms of androgen excess.
What each genotype means
Typical enzyme activity
You carry two copies of the common reference allele at this position in the CYP21A2 gene. Individuals with this genotype produce standard 21-hydroxylase enzyme levels and do not carry the p.Val281Leu variant linked to non-classic congenital adrenal hyperplasia. You are not considered at elevated carrier or personal genetic risk from this specific alteration.
Found in over 98% of individuals in most global populations, though slightly less frequent in Ashkenazi Jewish ancestry.
Carrier of non-classic CAH variant
You carry one copy of the p.Val281Leu pathogenic variant in the CYP21A2 gene. As an autosomal recessive condition, single-copy carriers typically do not develop congenital adrenal hyperplasia, although some studies report mild variations in androgen levels. If your reproductive partner also carries a CYP21A2 variant, there is a statistical likelihood of passing on reduced enzyme function to offspring.
Carried by approximately 1% to 2% of individuals of general European descent and up to 10% to 15% of individuals of Ashkenazi Jewish ancestry.
Reduced 21-hydroxylase activity
You carry two copies of the p.Val281Leu variant in the CYP21A2 gene, which is strongly associated with non-classic congenital adrenal hyperplasia. This genotype leads to partial 21-hydroxylase enzyme deficiency, which can manifest as mild androgen excess, irregular menses, acne, or reduced fertility, though some individuals remain completely asymptomatic. Clinical presentation varies considerably, so genetic results are best interpreted in consultation with an endocrinologist or medical geneticist alongside hormonal testing.
Very rare globally (less than 0.05%), but occurs in up to 1% to 2% of individuals within Ashkenazi Jewish populations.
What is the rs121908743 Variant?
The rs121908743 variant is a single nucleotide polymorphism located within the CYP21A2 gene on chromosome 6. In scientific literature, this specific change is widely recognized by the protein-level notation V281L, which indicates that the amino acid valine at position 281 has been replaced by leucine. This gene is situated in a complex region of the genome known as the RCCX locus, which is prone to structural variations and gene conversions. Because of this genomic complexity, identifying and interpreting variants in CYP21A2 requires specialized genetic testing techniques. The variant is categorized as a trait-associated marker, specifically linked to the non-classic form of 21-hydroxylase deficiency. It is important to note that while this variant is well-documented, its presence does not automatically result in a clinical diagnosis, as the manifestation of symptoms depends on the overall genetic context and the presence of other variants on both copies of the gene.
The Role of the CYP21A2 Gene
The CYP21A2 gene provides instructions for producing an enzyme called 21-hydroxylase. This enzyme plays a critical role in the adrenal glands, where it is responsible for the final steps in the production of cortisol, a vital hormone that helps the body respond to stress, maintain blood pressure, and regulate metabolism. When the CYP21A2 gene is altered, the activity of the 21-hydroxylase enzyme can be reduced or completely absent. A significant reduction in enzyme activity leads to a decrease in cortisol production and a simultaneous buildup of steroid precursors. These precursors are then diverted into the production of androgens, which are male-type sex hormones. In the non-classic form of the condition, the enzyme retains enough partial function to prevent the severe, life-threatening salt-wasting crises seen in classic forms, but it may still cause mild symptoms of androgen excess, such as acne, hirsutism, or irregular menstrual cycles.
Research and Clinical Associations
Research has consistently associated the V281L (rs121908743) variant with non-classic congenital adrenal hyperplasia (NCAH). Studies have shown that individuals who carry this variant, particularly when present on both copies of the gene or in combination with other pathogenic variants, may experience symptoms related to androgen excess. In clinical settings, NCAH is sometimes misdiagnosed as polycystic ovary syndrome (PCOS) due to overlapping symptoms like infertility and menstrual irregularities. The evidence linking this specific variant to NCAH is considered strong in the context of genetic counseling. However, it is important to recognize that the clinical expression of this variant is variable. Some individuals may be asymptomatic, while others may require medical management if they experience significant symptoms. If you have concerns about your health or symptoms related to hormone levels, it is essential to discuss your genetic findings with a qualified endocrinologist or a genetic counselor who can interpret these results in the context of your personal health history.
Population Frequency
The frequency of the rs121908743 variant varies significantly across different ancestral populations. In the general European population, the carrier frequency is estimated to be approximately 1% to 2%. However, the variant is notably more common in individuals of Ashkenazi Jewish descent, where the carrier frequency is estimated to be around 10%. This higher prevalence in specific populations is a well-documented phenomenon in genetic epidemiology. Because the condition is inherited in an autosomal recessive pattern, an individual typically needs to inherit the variant from both parents to be at a higher risk for the non-classic form of the condition. Understanding these population-specific frequencies is a key component of genetic screening programs, which aim to provide individuals with information about their carrier status for various inherited conditions.
What This Information Means for You
Learning about a genetic variant like rs121908743 can provide insight into your biological predispositions, but it is not a medical diagnosis. Genetic information is only one piece of a much larger puzzle that includes your environment, lifestyle, and other genetic factors. If you have received results indicating you carry this variant, it is important to avoid making assumptions about your health. You cannot use this information to diagnose yourself or to initiate any form of treatment. If you are experiencing symptoms or have a family history of adrenal conditions, consult with a healthcare professional. They can order appropriate diagnostic tests, such as an ACTH stimulation test, to determine if your hormone levels are within a normal range. Always consult with your clinician or pharmacist before making any decisions regarding your health or potential medical interventions.
How common is this variant?
The carrier frequency for this variant is approximately 1-2% in individuals of European descent and is significantly higher in Ashkenazi Jewish populations, reaching approximately 10%.
Frequently asked questions
Is rs121908743 the same as V281L?
Yes, rs121908743 is the unique identifier (rsID) used in scientific databases to refer to the specific genetic change commonly known as V281L in the CYP21A2 gene.
Does having the V281L variant mean I have a disease?
Not necessarily. Having the variant does not automatically mean you have a disease, as the condition is recessive and requires specific genetic combinations to manifest symptoms.
Can this variant cause infertility?
Non-classic congenital adrenal hyperplasia, which is associated with this variant, can sometimes present with symptoms like infertility or menstrual irregularities in women. However, these symptoms can also be caused by many other factors.
Should I get tested for this variant?
Genetic testing is a personal decision often made in consultation with a doctor or genetic counselor. It is typically considered if you have a family history of the condition or are experiencing symptoms that warrant investigation.
How is non-classic congenital adrenal hyperplasia treated?
Treatment for non-classic congenital adrenal hyperplasia is managed by endocrinologists and may involve hormone replacement therapy if symptoms are present. You should always discuss any potential treatment plans with your healthcare provider.
Sources & further reading
Educational information only, last refreshed 10/12/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121908743?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP21A2
Pathogenic variant associated with non-classic congenital adrenal hyperplasia presenting with hyperandrogenism, oligomenorrhea, and subfertility.
Pathogenic variant in CYP21A2 associated with 21-hydroxylase deficiency, used in reproductive carrier screening.
Pathogenic missense variant in CYP21A2 associated with 21-hydroxylase deficiency, a cause of congenital adrenal hyperplasia.
Well-characterized pathogenic missense variant (p.Pro30Leu) causing non-classic congenital adrenal hyperplasia and female hyperandrogenic subfertility.
This variant in the CYP21A2 gene is involved in steroid hormone metabolism and is noted in clinical databases.
This variant is classified as pathogenic and is associated with 21-hydroxylase deficiency.